<--- Back to Details
First PageDocument Content
Cancer organizations / Ovarian cancer / Breast cancer / Cancer survivor / Dana–Farber Cancer Institute / The Million Women Study / Ovarian Cancer National Alliance / Medicine / Oncology / Gynaecological cancer
Date: 2013-08-15 09:47:09
Cancer organizations
Ovarian cancer
Breast cancer
Cancer survivor
Dana–Farber Cancer Institute
The Million Women Study
Ovarian Cancer National Alliance
Medicine
Oncology
Gynaecological cancer

Defense Health Program Ovarian Cancer Research Program

Add to Reading List

Source URL: cdmrp.army.mil

Download Document from Source Website

File Size: 2,80 MB

Share Document on Facebook

Similar Documents

Journal of Machine Learning ResearchSubmitted 8/15; Revised 3/16; PublishedStructure-Leveraged Methods in Breast Cancer Risk Prediction

DocID: 1vq0d - View Document

Multicausality: Confounding - Assignment solutions 1. a. Reserpine is a risk factor. Overall, the incidence of breast cancer isper 100,000 women-years in reserpine users and 6.14 per 100,000 women-years in nonuser

DocID: 1vpNA - View Document

Frequently Asked Questions: Trainees seeking a PhD education in Cancer Biology or a related area with a focus on Breast Cancer Health Disparities. 1. What is the Komen Graduate Training in Disparities Research Grant (GT

DocID: 1voV1 - View Document

_____________________________________________________________ What to Do When Someone You Know Has Been Diagnosed with Breast Cancer [Last revised Mar 2014]

DocID: 1vlqg - View Document

Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1–mediated metabolism to the product 4′ hydroxy tangeretin

DocID: 1vl9e - View Document